Axogen, Inc. announced positive topline results from its REPOSE clinical study comparing standard-of-care neurectomy of symptomatic neuroma to neurectomy and protection of the terminated nerve end with Axoguard Nerve Cap. The post-marketing study met its primary endpoint for reduction in pain as measured by visual analog scale (p-value <0.05). Additional data analysis found that over the 12-month course of follow-up, the Axoguard Nerve Cap group demonstrated statistical superiority for reduction in the total pain reported by participants compared to the standard-of-care neurectomy group (p-value <0.05).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.82 USD | -0.15% | +8.77% | -0.15% |
May. 28 | Axogen, Inc. Announces the Opening of its Axogen Processing Center | CI |
May. 16 | AxoGen Initiates Rolling Submission to FDA For Avance Nerve Graft | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.15% | 298M | |
+7.31% | 217B | |
+12.99% | 194B | |
+19.71% | 143B | |
+30.60% | 111B | |
+0.65% | 64.3B | |
+15.23% | 52.94B | |
+2.06% | 49.53B | |
-5.49% | 38.31B | |
-0.22% | 35.22B |
- Stock Market
- Equities
- AXGN Stock
- News AxoGen, Inc.
- Axogen, Inc. Announces Positive Topline Results from Its REPOSE Clinical Study